Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2003

View Archived Issues

Three series of 5-HT2C agonists for schizophrenia and obesity claimed by Wyeth

New agents for Flaviviridae infections covered by ViroPharma patent

Nippon Shinyaku presents novel antipruritic agents

Sumitomo researchers design novel ACAT inhibitors for arteriosclerosis therapy

New MMP-13 inhibitors identified at Takeda

Yamanouchi scientists prepare and test new glycogen phosphorylase inhibitors

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

CGP-76030 inhibits proliferation of imatinib-resistant, Bcr/Abl-transformed murine bone marrow cells

Enhanced apoptosis with LAQ-824 and Apo2L/TRAIL cotreatment

CC-5079 induces NF-B-independent apoptosis of hematopoietic cancer cells

Potent in vitro effects of OSW-1 against human leukemia cells

U.S. launch of Risperdal Consta

Allos completes RSR-13 NDA filing

Treatment commences in pivotal European phase II trial of clofarabine for ALL

Collegium and Endo to develop abuse-resistant opioids

Discovery Partners and Allergan enter lead discovery collaboration

PDE4 inhibitor AWD-12-281 progresses through the clinic

ETC-1001 safe and well tolerated in phase I study

GBTherapeutics cleared to begin Canadian phase Ia trial of GT-1061

Emory University, GSK and NIMH team up to tackle depression and mood disorders

Cipralex approved in select European countries for social anxiety disorder

Immunomedics updates progress of key antibody product candidates

New site added to international phase II study of Litx

Merck & Co. and Actelion join forces to develop renin inhibitors

MLN-2704 granted fast track designation

First NO compound from Merck/NitroMed partnership enters clinical testing

Certican completes European mutual recognition procedure

Phytopharm cleared to commence phase I testing of PYM-50018 for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 9, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...